HCC
Warrior Met Coal, Inc.
$82.62
+0.51
(+0.61%)
Mkt Cap
4.38B
Volume
279,069
52W Range
48.77-110.39
Sector
Energy
Beta
0.67
EPS (TTM)
2.62
P/E Ratio
31.68
Revenue (TTM)
1.47B
Rev Growth (5Y)
+10.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$70.38
Overvalued
moderate signal
17.9% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C+
Other Commodity Producers
61.7 / 100 composite
A commodity producer — graded A–F vs. similar companies.
Company Description
Warrior Met Coal, Inc. specializes in the extraction and international distribution of coking coal, a critical raw material for steel production. The firm operates a pair of underground mines situated in Alabama. Its primary client base consists of blast furnace steel producers, predominantly located across Europe, South America, and Asia. In addition to coal, the company also sells natural gas, which is recovered as a byproduct of its mining activities. Established as a corporation in 2015, Warrior Met Coal, Inc. maintains its headquarters in Brookwood, Alabama.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.53B | 1.68B | 1.74B | 1.06B | 782.74M | 1.27B | 1.38B | 1.17B | 369.02M | 544.73M |
| Net Income | 57.00M | 250.60M | 478.63M | 641.30M | 150.88M | (35.76M) | 301.70M | 696.79M | 455.05M | (111.49M) | (310.58M) |
| EPS | 1.08 | 4.79 | 9.21 | 12.42 | 2.94 | -0.70 | 5.87 | 13.19 | 8.62 | -2.12 | -5.90 |
| Free Cash Flow | (91.02M) | (89.77M) | 209.43M | 633.16M | 293.65M | 25.14M | 425.54M | 460.70M | 341.89M | (66.84M) | (196.79M) |
| FCF / Share | -1.73 | -1.72 | 4.03 | 12.27 | 5.72 | 0.49 | 8.28 | 8.72 | 6.48 | -1.27 | -3.74 |
| Operating CF | 229.25M | 367.45M | 701.11M | 841.90M | 351.54M | 112.63M | 532.81M | 559.40M | 434.51M | (49.88M) | (131.82M) |
| Total Assets | 2.78B | 2.59B | 2.36B | 2.03B | 1.46B | 1.39B | 1.34B | 1.40B | 993.32M | 947.63M | 802.14M |
| Total Debt | 270.94M | 173.04M | 173.24M | 335.68M | 391.86M | 418.38M | 374.86M | 468.99M | 345.91M | 6.57M | 1.41B |
| Cash & Equiv | 299.96M | 491.55M | 738.20M | 829.48M | 395.84M | 211.92M | 193.38M | 205.58M | 35.47M | 150.04M | 79.76M |
| Book Value | 2.14B | 2.09B | 1.87B | 1.45B | 871.98M | 725.24M | 765.58M | 712.61M | 413.02M | 752.97M | (820.86M) |
| Return on Equity | 0.03 | 0.12 | 0.26 | 0.44 | 0.17 | -0.05 | 0.39 | 0.98 | 1.10 | -0.15 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 458.59M | 384.11M | 327.88M | 298.83M | 298.23M | 297.46M | 327.72M | 396.52M | 503.51M | 363.80M | 423.49M | 379.66M |
| Net Income | 72.34M | 22.96M | 36.60M | 5.61M | (8.17M) | 1.14M | 41.77M | 70.71M | 136.99M | 128.88M | 85.38M | 82.09M |
| EPS | 1.37 | 0.44 | 0.70 | 0.11 | -0.16 | 0.02 | 0.80 | 1.35 | 2.63 | 2.48 | 1.64 | 1.58 |
| Free Cash Flow | (91.86M) | (18.12M) | 12.75M | (37.42M) | (57.59M) | (76.47M) | (53.67M) | 36.01M | 4.36M | 64.24M | 32.05M | (11.61M) |
| FCF / Share | -1.74 | -0.35 | 0.24 | -0.71 | -1.10 | -1.46 | -1.03 | 0.69 | 0.08 | 1.23 | 0.62 | -0.22 |
| Operating CF | (11.73M) | 76.09M | 104.69M | 37.55M | 10.92M | 54.21M | 62.21M | 146.97M | 104.06M | 245.09M | 138.57M | 124.51M |
| Total Assets | 2.82B | 2.78B | 2.68B | 2.65B | 2.62B | 2.59B | 2.58B | 2.56B | 2.48B | 2.36B | 2.22B | 2.24B |
| Total Debt | 266.50M | 270.94M | 236.57M | 235.71M | 172.29M | 173.04M | 170.38M | 170.92M | 172.23M | 173.24M | 176.40M | 324.30M |
| Cash & Equiv | 202.60M | 299.96M | 336.28M | 383.25M | 454.93M | 491.55M | 583.16M | 709.02M | 693.86M | 738.20M | 686.81M | 827.42M |
| Book Value | 2.20B | 2.14B | 2.12B | 2.08B | 2.08B | 2.09B | 2.09B | 2.05B | 1.98B | 1.87B | 1.75B | 1.66B |
| Return on Equity | 0.03 | 0.01 | 0.02 | 0.00 | -0.00 | 0.00 | 0.02 | 0.03 | 0.07 | 0.07 | 0.05 | 0.05 |
HCC News
HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
Warrior Met Coal Inc (HCC) Shares Fall 4.3% -- What GF Score of 81 Tells Investors
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
This $4 Million Warrior Met Coal Sale May Be More About Profit Taking Than Coal Prices
Warrior Met Coal, Inc. (HCC) Q1 2026 Earnings Call Transcript
Warrior Met Coal (HCC) Tops Q1 Earnings and Revenue Estimates
Warrior Reports First Quarter 2026 Results